| Behbahani Ali |
Non-Executive Director |
SpyGlass Pharma, Inc. (SGP)
|
2026-02-09 |
$16.00 |
0.0% |
937,500
|
$15,000,000 |
| Behbahani Ali |
Non-Executive |
MBX Biosciences, Inc. (MBX)
|
2024-09-16 |
$16.00 |
0.0% |
500,000
|
$8,000,000 |
| Behbahani Ali |
Non-Executive |
Savara Inc (SVRA)
|
2023-07-17 |
$3.00 |
51.3% |
333,333
|
$999,999 |
| Behbahani Ali |
Non-Executive |
Trevi Therapeutics, Inc. (TRVI)
|
2022-04-11 |
$1.90 |
63.2% |
3,580,526
|
$6,802,999 |
| Behbahani Ali |
Non-Executive Director |
Monte Rosa Therapeutics, Inc. (GLUE)
|
2021-06-28 |
$19.00 |
-68.4% |
1,050,000
|
$19,950,000 |
| Behbahani Ali |
Non-Executive |
Bright Health Group Inc. (BHG)
|
2021-06-28 |
$115200.00 |
-100.0% |
304
|
$34,999,992 |
| Behbahani Ali |
Non-Executive |
Marker Therapeutics, Inc. (MRKR)
|
2021-03-16 |
$17.50 |
-82.1% |
571,428
|
$9,999,999 |
| Behbahani Ali |
Non-Executive |
Regulus Therapeutics Inc. (RGLS)
|
2020-12-04 |
$6.22 |
-74.9% |
439,860
|
$2,735,930 |
| Behbahani Ali |
Non-Executive |
Metacrine, Inc. (MTCR)
|
2020-09-18 |
$13.00 |
-95.5% |
769,230
|
$9,999,990 |
| Behbahani Ali |
Non-Executive Director |
Black Diamond Therapeutics, Inc. (BDTX)
|
2020-02-03 |
$19.00 |
-70.6% |
800,000
|
$15,200,000 |
| Behbahani Ali |
Non-Executive Director |
Adaptimmune Therapeutics PLC (ADAP)
|
2020-01-24 |
$0.67 |
66.5% |
7,500,000
|
$5,000,250 |
|
|
|
|
|
Return |
Profit / (loss) |
Cost |
|
|
|
Total |
|
-55.2% |
$-71,052,739 |
$128,689,160 |